TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11555061

Group type: EXPERIMENTAL
Intervention: Preintervention treatment with parenteral antibiotics (PA) when PA were recommended by the guidelines (n = 127)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Preintervention treatment with oral antibiotics (OA) when OA were indicated by the guidelines (n = 99)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Postintervention treatment with PA and OA according to the guidelines
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Postintervention episodes treated with PA in accordance with the guidelines
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Preintervention episodes with indications for PA
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Preintervention episodes with indications for OA
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Postintervention episodes with indications for PA
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Postintervention episodes with indications for OA
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Comparison of 30-day mortality preintervention and postintervention for episodes with guideline indications for OA
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Comparison of 30-day mortality preintervention and postintervention for episodes with guideline indications for PA
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of 30-day mortality
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Hospital admissions for episodes on NHAP
Number of subjects: 350
Study: 10021958

Group type: EXPERIMENTAL
Intervention: 1 ml saline
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 5 ml saline
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 10 ml saline
Number of subjects: 70
Study: 7917685

Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intermittent ischaemic arrest
Number of subjects: 20
Study: 3379782

Group type: COMPARATOR
Intervention: VEPA (vincristine, cyclophosphamide, prednisolone and doxorubicin)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: VEPA-M (VEPA plus methotrexate)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Low-risk group
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Moderate-risk group
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 82
Study: 31122721

Group type: EXPERIMENTAL
Intervention: Patients born in November
Number of subjects: 12263

Group type: EXPERIMENTAL
Intervention: Patients born in December
Number of subjects: 12263

Group type: EXPERIMENTAL
Intervention: Patients born in February
Number of subjects: 12263

Group type: EXPERIMENTAL
Intervention: Patients born in January to March and May to September
Number of subjects: 12263

Group type: EXPERIMENTAL
Intervention: Patients born in winter
Number of subjects: 12263

Group type: COMPARATOR
Intervention: Patients across birth seasons
Number of subjects: 12263
Study: 29234746

Group type: EXPERIMENTAL
Intervention: 5 or 6 mm long implants
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10 mm long implants
Number of subjects: 20
Study: 26323921

Group type: EXPERIMENTAL
Intervention: Nimotuzumab (200 mg) with docetaxel (60 mg/m2) and carboplatin (AUC = 5)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Chemotherapy (docetaxel 60 mg/m2 and carboplatin AUC = 5)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Nimotuzumab with chemotherapy
Number of subjects: 59
Study: 23447123

Group type: EXPERIMENTAL
Intervention: Insulin administered according to the customary insulin:carbohydrate ratio
Number of subjects: 19
Study: 21672597

Group type: EXPERIMENTAL
Intervention: Switching from 9-10 mg ISO tar yield cigarette to 4 mg ISO tar yield cigarette
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Switching from 4-6 mg ISO tar yield cigarette to 1 mg ISO tar yield cigarette
Number of subjects: 300

Group type: COMPARATOR
Intervention: Non-switching control group smoking their usual ISO tar yield cigarette
Number of subjects: 300
Study: 19929644

Group type: EXPERIMENTAL
Intervention: Diaphragm and lubricant gel intervention
Number of subjects: 0
Study: 17036703

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) pulpotomy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Calcium hydroxide (Ca(OH)2) pulpotomy
Number of subjects: 15
Study: 15679256

Group type: EXPERIMENTAL
Intervention: Targeted drugs in combination with ionizing radiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ionizing radiation alone
Number of subjects: 0
Study: 10678543

Group type: EXPERIMENTAL
Intervention: ACE inhibitor ramipril (5 mg/day for 3 weeks)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: AT1B losartan (50 mg/day for 3 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control L-arginine infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: ACE inhibitor ramipril and AT1B losartan
Number of subjects: 9
Study: 9549634

Group type: EXPERIMENTAL
Intervention: Enalapril/Diltiazem ER alone (n = 14)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Enalapril/Diltiazem ER with other agents (n = 79)
Number of subjects: 93
Study: 8349942

Group type: EXPERIMENTAL
Intervention: Allergen challenge
Number of subjects: 15

Group type: COMPARATOR
Intervention: Diluent challenge
Number of subjects: 15
Study: 3484691

Group type: EXPERIMENTAL
Intervention: Digoxin, 0.375 mg/day, loaded with doubled doses on days 1 and 2, for 14 days.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bepridil, 300 mg/day, loaded with 900 mg on day 8.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Concurrent dosing of digoxin and bepridil.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Digoxin alone.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bepridil alone.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Concurrent dosing of both drugs.
Number of subjects: 48
Study: 28322651

Group type: EXPERIMENTAL
Intervention: Spiritual care
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no spiritual care)
Number of subjects: 62
Study: 26092233

Group type: EXPERIMENTAL
Intervention: lipegfilgrastim 6 mg
Number of subjects: 202

Group type: COMPARATOR
Intervention: pegfilgrastim 6 mg
Number of subjects: 202
Study: 24694622

Group type: EXPERIMENTAL
Intervention: Well London interventions (activities focused on healthy eating, physical exercise, and mental health and well-being)
Number of subjects: 61
Study: 22647280

Group type: EXPERIMENTAL
Intervention: Chair-rising exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: One-leg standing exercise
Number of subjects: 30
Study: 19896200

Group type: EXPERIMENTAL
Intervention: Re-ChORD (integrative treatment program including medication management, interpersonal psychotherapy, and occupational therapy)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 64
Study: 18847162

Group type: EXPERIMENTAL
Intervention: Thyroxine-treated patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study: 16181936

Group type: EXPERIMENTAL
Intervention: Real acupuncture needles
Number of subjects: 51

Group type: COMPARATOR
Intervention: Telescopic sham needles
Number of subjects: 51
Study: 11936063

Group type: EXPERIMENTAL
Intervention: Home-based aerobic exercise intervention (15 weeks, 20 minutes three times per week)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 99
Study: 10556613

Group type: EXPERIMENTAL
Intervention: Myopic subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emmetropic control subjects
Number of subjects: 0
Study: 8918674

Group type: EXPERIMENTAL
Intervention: Routine administration of rG‐CSF on the 6th day after BEP chemotherapy (group A)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Administration of rG‐CSF after granulocytopenia of 1,500/mm3 had developed (group B)
Number of subjects: 15

Group type: COMPARATOR
Intervention: BEP chemotherapy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rG‐CSF in group A
Number of subjects: 15
Study: 1747882

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste with sodium monofluorophosphate, calcium glycerophosphate supplement, and calcium carbonate abrasive
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste with sodium monofluorophosphate and sodium fluoride, calcium glycerophosphate supplement, and calcium carbonate abrasive
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste with sodium fluoride and silica abrasive
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fluoride-free toothpaste with silica abrasive
Number of subjects: 19
Study: 6817771

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Clovoxamine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 30950535

Group type: EXPERIMENTAL
Intervention: WeChat-based life review program plus routine care
Number of subjects: 92

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 92
Study: 28763316

Group type: EXPERIMENTAL
Intervention: Calcium chloride (5 mg/kg) coadministered with neostigmine (25 μg/kg) and atropine (15 μg/kg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Normal saline coadministered with neostigmine (25 μg/kg) and atropine (15 μg/kg)
Number of subjects: 53
Study: 26243641

Group type: EXPERIMENTAL
Intervention: Education with public commitment and reminder
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Education with infrastructure promotion and reminder
Number of subjects: 408

Group type: COMPARATOR
Intervention: Standard approach (education only)
Number of subjects: 408
Study: 23468553

Group type: EXPERIMENTAL
Intervention: Maternal lipid-based nutrient supplements (LNS) during lactation
Number of subjects: 1619

Group type: COMPARATOR
Intervention: No LNS (Control)
Number of subjects: 1619
Study: 21699777

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with fast-track multimodal management
Number of subjects: 93

Group type: COMPARATOR
Intervention: Laparoscopic surgery with standard care
Number of subjects: 93

Group type: COMPARATOR
Intervention: Open surgery with fast-track care
Number of subjects: 93

Group type: COMPARATOR
Intervention: Open surgery with standard care
Number of subjects: 93
Study: 18057307

Group type: EXPERIMENTAL
Intervention: Sevelamer (n = 25, 12 males)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Calcium acetate (n = 25, 13 males)
Number of subjects: 50
Study: 16490808

Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) 20 mg for 7 days with CyA 100 mg coadministered on day 7
Number of subjects: 0

Group type: COMPARATOR
Intervention: CyA 100 mg alone
Number of subjects: 0
Study: 11818350

Group type: EXPERIMENTAL
Intervention: Open access follow-up
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Trial experience
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Shared care guideline awareness
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Management problems
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Cumulative Encounter Form usage
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Support for written guidelines
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Establishment of GI nurse practitioner
Number of subjects: 180
Study: 10564333

Group type: EXPERIMENTAL
Intervention: Acrivastine (8 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 60
Study: 8563277

Group type: EXPERIMENTAL
Intervention: Computerized decision support system for the management of mechanical ventilation in ARDS patients
Number of subjects: 0
Study: 2162875

Group type: EXPERIMENTAL
Intervention: Na-Li CT
Number of subjects: 22

Group type: COMPARATOR
Intervention: Resting blood pressure
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standing DBP
Number of subjects: 22
Study: 913121

Group type: EXPERIMENTAL
Intervention: 300 mg flurbiprofen daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: 150 mg indomethacin daily
Number of subjects: 24
Study: 7225165

Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg tid for 4 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg tid for 9 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg tid for 9 weeks in 10 subjects with lipoprotein cholesterol fractionation
Number of subjects: 30
Study: 30778571

Group type: EXPERIMENTAL
Intervention: EOD1 (Essential oil blends and Vitamin D3; 50 μg 25‐OH‐D3/kg diet, 15 mg CRINA Poultry/kg diet)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: EOD2 (Essential oil blends and Vitamin D3; 69 μg 25‐OH‐D3/kg diet, 30 mg CRINA Poultry/kg diet)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: EOD3 (Essential oil blends and Vitamin D3; 138 μg 25‐OH‐D3/kg diet, 50 mg CRINA Poultry/kg diet)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: EOD2 and EOD3
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: EOD1, EOD2, and EOD3
Number of subjects: 800

Group type: COMPARATOR
Intervention: CON (Control group, unvaccinated birds fed basal diet)
Number of subjects: 800

Group type: COMPARATOR
Intervention: CCO (CON + coccidian oocysts vaccinated birds)
Number of subjects: 800
Study: 29851824

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg of rocuronium intravenously (group L)
Number of subjects: 98

Group type: COMPARATOR
Intervention: 0.6 mg/kg of rocuronium (group C)
Number of subjects: 98
Study: 27439370

Group type: EXPERIMENTAL
Intervention: Abediterol 0.625 μg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Abediterol 2.5 μg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Abediterol 5 μg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Abediterol 10 μg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Indacaterol 150 μg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 24128379

Group type: EXPERIMENTAL
Intervention: Integrated/co-located (ICL) healthcare
Number of subjects: 296

Group type: COMPARATOR
Intervention: Non-co-located (NCL) healthcare
Number of subjects: 296

Group type: COMPARATOR
Intervention: Harm reduction/outreach (HRO) settings
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Opioid substitution therapy (OST)
Number of subjects: 296
Study: 22292061

Group type: EXPERIMENTAL
Intervention: Intervention by clinical pharmacists including answering questions of physicians and nurses, giving advice on treating patients, checking prescriptions and patient counseling at discharge.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group without clinical pharmacist interventions.
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Intervention by clinical pharmacists.
Number of subjects: 160
Study: 21054896

Group type: COMPARATOR
Intervention: Amniotomy (group 1)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Oxytocin (group 2)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Both amniotomy and oxytocin (group 3)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group (group 4)
Number of subjects: 213
Study: 17516484

Group type: EXPERIMENTAL
Intervention: Entacapone (ENT), 3 to 5 times daily
Number of subjects: 161

Group type: COMPARATOR
Intervention: Cabergoline (CBG), titrated to a maximum of 6 mg/d
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Entacapone (ENT)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Cabergoline (CBG)
Number of subjects: 161
Study: 16330964

Group type: EXPERIMENTAL
Intervention: gentian violet
Number of subjects: 146

Group type: COMPARATOR
Intervention: nonadherent absorbent dressing
Number of subjects: 146
Study: 12390384

Group type: EXPERIMENTAL
Intervention: Ranitidine 100 mg intravenously twice daily followed by oral ranitidine 150 mg twice daily for 5 years
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Ranitidine in non-transfused patients (n = 202)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Ranitidine in non-transfused patients without postoperative infectious complications (n = 170)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Ranitidine in curatively resected patients (including Dukes' stage, age, gender, tumour location, blood transfusion, postoperative infectious complications)
Number of subjects: 740

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 740
Study: 10090428

Group type: EXPERIMENTAL
Intervention: Sparfloxacin 400 mg loading dose on day 1, followed by 200 mg once daily for 10 days
Number of subjects: 342

Group type: COMPARATOR
Intervention: Clarithromycin 250 mg twice daily for 10 days
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 342

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 342
Study: 7751483

Group type: EXPERIMENTAL
Intervention: 8-week intervention combining education with behavior skills training
Number of subjects: 246

Group type: COMPARATOR
Intervention: Educational program
Number of subjects: 246
Study: 2281760

Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 47
Study: 373395

Group type: EXPERIMENTAL
Intervention: Noise exposure at 95 dB A
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Noise exposure at 75 and 85 dB A
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Post-noise stimulation
Number of subjects: 18
Study: 31153360

Group type: COMPARATOR
Intervention: Dexmedetomidine 0 mcg/kg (group 1)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Dexmedetomidine 0.3 mcg/kg (group 2)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 mcg/kg (group 3)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.9 mcg/kg (group 4)
Number of subjects: 180
Study: 28872503

Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (manual superficial sliding movements)
Number of subjects: 30
Study: 25595113

Group type: EXPERIMENTAL
Intervention: Arm vein (AV) bypass
Number of subjects: 64

Group type: COMPARATOR
Intervention: Contralateral greater saphenous vein (CGSV) bypass
Number of subjects: 64
Study: 24448227

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg daily for 24 months
Number of subjects: 71

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg daily for 24 months
Number of subjects: 71
Study: 21917822

Group type: EXPERIMENTAL
Intervention: ASK8007
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19733003

Group type: EXPERIMENTAL
Intervention: Ropinirole (RPN)
Number of subjects: 423
Study: 17263650

Group type: EXPERIMENTAL
Intervention: TPV/r 500 mg/100 mg
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: TPV/r 500 mg/200 mg
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: TPV/r 750 mg/200 mg
Number of subjects: 216
Study: 15024665

Group type: EXPERIMENTAL
Intervention: Cooling (ice bag on ankle dorsiflexors)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no cooling)
Number of subjects: 6
Study: 12473477

Group type: EXPERIMENTAL
Intervention: Cefazolin (1 g)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Ampicillin (1 g)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo (3 mL sterile water)
Number of subjects: 330
Study: 9666830

Group type: EXPERIMENTAL
Intervention: 5 times weekly narrow-band TL-01 UVB phototherapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: 3 times weekly narrow-band TL-01 UVB phototherapy
Number of subjects: 21
Study: 7648653

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg TID)
Number of subjects: 946

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 946
Study: 2667654

Group type: EXPERIMENTAL
Intervention: Adjuvant cytotoxic chemotherapy (76 patients)
Number of subjects: 399

Group type: COMPARATOR
Intervention: No systemic adjuvant treatment (93 patients)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: CMF chemotherapy (oral cyclophosphamide and intravenous methotrexate and 5‐fluorouracil) for 12 cycles over one year
Number of subjects: 399
Study: 908220

Group type: EXPERIMENTAL
Intervention: fenoterol 400 μg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: fenoterol 200 μg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: fenoterol 100 μg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: isoproterenol 150 μg
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All drug regimens
Number of subjects: 20
Study: 31549290

Group type: EXPERIMENTAL
Intervention: First pass radionuclide angiography (FPRNA)
Number of subjects: 46
Study: 29728338

Group type: EXPERIMENTAL
Intervention: Supplementation with Magnesium (Mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control treatment with maltose
Number of subjects: 16
Study: 28210090

Group type: EXPERIMENTAL
Intervention: Stellate ganglion block treatment (experimental group, n = 90)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral sulfasalazine treatment (control group, n = 30)
Number of subjects: 120
Study: 26383493

Group type: EXPERIMENTAL
Intervention: Pistachio diet (20% of total energy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control diet (without pistachios)
Number of subjects: 30
Study: 23163421

Group type: EXPERIMENTAL
Intervention: Single-pulse TMS delivered at 120% distance-adjusted individual motor threshold over rFEF
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Single-pulse TMS delivered at 120% distance-adjusted individual motor threshold over rIFG
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Single-pulse TMS delivered at 120% distance-adjusted individual motor threshold over rPPC
Number of subjects: 21
Study: 21994957

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conservative treatment (control group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: XLH reference population
Number of subjects: 16
Study: 18505226

Group type: EXPERIMENTAL
Intervention: Single Bond (3M)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (Kuraray)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Xeno III (Dentsply)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond with 37% phosphoric acid gel
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Xeno III with 37% phosphoric acid gel
Number of subjects: 32
Study: 16455632

Group type: EXPERIMENTAL
Intervention: Initial PET scan with 3.3-4 MBq/kg of 18F-fluorocholine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Delayed PET scan with 3.3-4 MBq/kg of 18F-fluorocholine
Number of subjects: 26